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Abstract This study evaluated the impact of family his-
tory (FH) on tumor detection, the patient’s age and tumor
size at diagnosis in breast cancer (BC). Furthermore, we
investigated whether the impact of FH on these features
was dependent on degree of relationship, number of rela-
tives with a BC history, or the age of the affected relative at
the time that her BC was diagnosed. Out of the entire
cohort (n = 1,037), 244 patients (23.5 %) had a positive
FH; 159 (15.3 %) had first-degree relatives affected with
BC and 85 patients (8.2 %) had second-degree affected
relatives. Compared to women who had no BC-affected
relatives, the tumors of women who had positive FH were
more often found by radiological breast examination (RBE:
31.7 %/27.2 %, p = 0.008), and they were smaller (gen-
eral tumor size: 21.8 mm/26.4 mm, p = 0.003; size of
tumors found by breast self-examination (BSE): 26.1 mm/
30.6 mm, p = 0.041). However, this positive effect of
increased use of BC screening and smaller tumor sizes
was only observed in patients whose first-degree relatives
were affected (comparison with second-degree affected
relatives: RBE: 43.8 %/24.7 %; odds ratio 2.38,
p = 0.007; general tumor size: 19.3 mm/26.3 mm; mean
difference (MD) -6.9, p = 0.025; tumor size found by
BSE: 22.5 mm/31.0 mm; MD -8.5, p = 0.044). When
more second-degree relatives or older relatives were
diagnosed with BC, the tumors of these patients were
similarly often detected by RBE (relationship: 24.7 %/
27.2 %, p = 0.641; age: 33.7 %/27.2 %, p = 0.177) and
had similar tumor sizes (general size: 26.3 mm/26.4 mm,
p = 0.960; BSE: 31.0 mm/30.6 mm, p = 0.902) as those
of women without a FH. Women with a positive FH gen-
erally use mammography screening more often and per-
ceive changes in the breast earlier than women without
such history. The increased awareness of BC risk decreases
if the relationship is more distant.
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Introduction
It is widely recognized that a woman’s risk of developing
breast cancer (BC) is increased if she has a family history
(FH) of the disease [1, 2]. In Western countries, the life-
time excess incidence of BC is 5.5 % for women with one
affected first-degree relative and 13.3 % for women with
two [1].
This study evaluates to what extent established radio-
logical screening methods for BC detection were utilized in
BC patients with a positive FH, compared to women
without affected relatives. The increased frequency of
radiological examinations in women with a positive FH
might demonstrate how personal and familial experiences
with BC can influence individuals’ behaviors, thus leading
to earlier detection of the disease [2–6]. Furthermore, the
impact of FH on the patient’s age at diagnosis and tumor
size at diagnosis was analyzed. As a next step, we inves-
tigated whether the impact of FH on tumor detection,
patient’s age and tumor size was dependent on factors such
as degree of relationship (first-degree vs. second-degree),
number of relatives with a history of BC (1 vs. C1), or the
age of the affected relative at the time that her BC was
diagnosed (\50 vs. C50 years).
During the last decade, there have only been a few
studies which evaluated the impact of FH on BC detection
and tumor size in BC patient cohorts [7–9]. To our
knowledge, our study is the first comprehensive analysis of
the impact of FH on BC detection and tumor size based on
a more recent population-based cohort (1990–2009) which
does not exclusively consider a subgroup of younger BC
patients [8], but rather also analyzes women at an age in
which BC mainly occurs (women up to and including
70 years of age).
Patients and methods
Data from the prospective relational Basel Breast Cancer
Database (BBCD), which includes all newly diagnosed
primary invasive BC cases treated at the University
Women’s Hospital Basel, Switzerland since 1990 provided
the basis for this study. This institution comprises the
largest BC center in the canton of Basel and is an adequate
representation of the regional population. Within this
database, disease-specific clinical and histopathological
data, treatment characteristics, personal and family history
as well as outcome data was recorded. For this study, data
from female patients up to and including 2009, who were
B70 years at diagnosis, was analyzed (n = 1,056). Since
the goal of the study was to evaluate the impact of FH on
tumor detection method and tumor size, 19 cases with
inflammatory BC were excluded from further analysis. Due
to the nature of inflammatory carcinomas, which arise
rapidly, affect large parts of the breast, and often have no
underlying definable mass, these cases are not suitable for
evaluating tumor detection methods and tumor size. In
total, our study cohort comprised 1,037 patients.
Family history
The criterion for a positive FH of BC was met when a
patient reported:
• one or more first-degree (mother, sister, daughter)
affected relatives, n = 159,
• one or more second-degree (aunt, grandmother)
affected relatives, n = 107.
In 22 cases, the patients had both first-degree and sec-
ond-degree affected relatives; we placed these patients in
the ‘‘first-degree relative’’-category, leading to 85 patients
being placed in the ‘‘second-degree relative’’-category.
For patients with a positive FH of BC, the number of BC
affected relatives and their age at diagnosis (\50 vs.
C50 years) was evaluated. Thirteen cases (first-degree
relatives, n = 10, second-degree relatives, n = 3), in
which two or more relatives had been diagnosed in both the
younger and older ages, were considered as ‘‘\50 years’’
only.
Clinicopathological data
The following data was available for all patients: age at
initial diagnosis, histological subtype, grading, hormonal
receptor (HR) status, tumor stage according to the Amer-
ican Joint Committee on Cancer (AJCC)/International
Union Against Cancer (UICC) TNM Classification [10,
11]. Because HER-2 status has been routinely assessed for
all patients since 2002, we included data from 2002–2009
only in the analysis of this particular characteristic. Car-
cinomas of the triple negative subtype are characterized by
a lack of expression of the estrogen receptor, progesterone
receptor, and HER2.
Tumor size
For most of our patients (n = 976, 94.1 %), the size of the
primary tumor was measured during pathological exami-
nation of the surgically resected lesion. In 40 patients
(3.9 %; positive FH: n = 8, negative FH: n = 32), where
neoadjuvant therapy was given, the pre-therapeutic clini-
cally assessed tumor sizes were used. The same was the
case for 21 patients (2.0 %; positive FH: n = 3; negative
FH: n = 19), where no surgery was performed.
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Of the entire study cohort, 20 patients presented with
synchronous bilateral BC (1.9 %); of these cases, the tumor
with the more advanced tumor size (‘‘reference lesion’’)
was considered for analysis.
Tumor detection method
The following two main methods were analyzed:
1. breast self-examination (BSE), n = 600 (57.9 %)
2. radiological breast examination (RBE), n = 253
(24.4 %)
Cases in which the tumor was found by a physician
during a clinical breast examination [CBE, n = 151
(14.6 %)] were not considered in the diagnostic method
analysis, because, contrary to BSE and the utilization of
RBE, CBE does not necessarily reflect the patient’s
awareness of early BC detection. The following patients
were also excluded from this part of analysis: 13 patients
(1.2 %), in which other detection modes apart from the
ones mentioned above were used, and 20 patients (1.9 %),
in which the method of tumor detection was not reported in
the clinical files.
Data collection methods and study design were
approved by the Ethics Committee of the University of
Basel.
Statistical methods
Comparisons between nominal parameters were made
using the Fisher exact test. In the case of the dependent
variables age and tumor size, univariate linear regression
analysis was performed. Results are presented as differ-
ences of means (MD) with corresponding 95 % confidence
intervals (95 % CI) and p values. In the case of the binary
dependent variable (detection method), logistic regressions
were performed. Results are presented as odds ratios (OR)
with the corresponding 95 % CI and p values. In all sta-
tistical tests the level of significance was p \ 0.05. All
evaluations were performed with R Development Core
Team software, version 13.1. The study is exploratory;
therefore, no adjustments for multiple comparisons were
done.
Results
Out of the entire cohort (n = 1,037), 244 patients (23.5 %)
had a positive FH for BC. Of these, 159 (15.3 %) had first-
degree relatives affected by BC and 85 patients (8.2 %) had
second-degree affected relatives only. Table 1 lists the
number of relatives with a history of BC and the age group
of the affected relative at the time that her BC was
diagnosed.
Pathological characteristics (Table 2)
Comparing the incidence of histological subtypes, there
were more lobular carcinomas in patients with a positive
FH than in those without FH (16.9 vs. 11.7 %, p = 0.037).
Patients with a positive FH showed less commonly estab-
lished indicators of tumor aggressiveness such as poorly
differentiated carcinomas (G3: 33.9 vs. 46.6 %,
p \ 0.001), a negative HR-negative status (13.5 vs.
19.2 %, p = 0.052) and triple-negative subtype (6.5 vs.
13.6 %, p = 0.007).
Age at diagnosis (Tables 2 and 3)
There was no significant difference between patients with
and without FH with respect to age at diagnosis (53.8 vs.
54.8 years, p = 0.201). However, patients with a positive
FH, who had only second-degree BC affected relatives,
were significantly younger when compared with patients
who had no FH (51.2 vs. 54.8 years, MD -3.6 years, 95 %
CI -5.9 to -1.3, p = 0.002), as well as patients with a
positive FH and first-degree BC affected relatives (51.2 vs.
55.2 years, MD -4.0 years, 95 % CI -6.7 to -1.2,
p = 0.004). There was a similar age distribution in patients
with no FH and those who had a positive FH with first-
degree BC affected relatives (54.8 vs. 55.2 years,
p = 0.652).
Patients whose relatives were diagnosed with BC at a
younger age (\50 years) were themselves significantly
younger at diagnosis than patients with negative FH (51.7
vs. 54.8 years, MD -3.1 years, 95 % CI -5.4 to -0.7,
p = 0.009) and patients with a positive FH whose relatives
were diagnosed with BC at an older age (51.7 vs.
56.1 years, MD -4.4 years, 95 % CI -7.3 to -1.6,
p = 0.002). Hereby, the number of affected relatives was
not found to have a substantial impact upon age at diag-
nosis (p = 0.440).
Tumor detection method: radiological breast
examination versus self-examination (Table 2 and 4)
Compared to the tumors of patients without FH, the lesions
of patients who had a positive FH were more often found
by RBE (37.1 vs. 27.2 %, p = 0.008). Within the group of
patients with a positive FH the tumors were significantly
more often found by RBE in patients with first-degree BC
affected relatives than in those with second-degree affected
relatives (43.8 vs. 24.7 %; OR 2.38, 95 % CI 1.27–4.54,
p = 0.007). In patients with a positive FH who had only
second-degree BC affected relatives, the tumors were
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found just as often by RBE as in patients without FH (24.7
vs. 27.2 %, p = 0.641).
In patients whose relatives were \50 years of age at
their BC diagnosis, we found that the tumors tended to be
more often found by RBE compared to patients whose
relatives were diagnosed with BC at an older age (47.3 vs.
33.7 %; OR 1.79, 95 % CI 1.00–3.23, p = 0.067; com-
parison with patients without FH: 47.3 vs. 27.2 %; OR
2.40, 95 % CI 1.47–3.90, p \ 0.001). In patients whose
relatives were diagnosed with BC at a more advanced age
(C50 years), this observation was not made (33.7 vs.
27.2 %, p = 0.177). The number of the affected relatives
was not relevant (p = 0.158).
Tumor size (Table 2 and 5)
Compared to patients without FH, patients with a positive
FH had smaller tumors at diagnosis (21.8 vs. 26.4 mm,
p = 0.003). Within the group of patients with a positive
FH, patients with first-degree BC affected relatives had
smaller tumors than those with second-degree affected
relatives (19.3 vs. 26.3 mm; MD -6.9, 95 % CI -13.0 to
-0.9, p = 0.025). The tumor sizes of patients with a
positive FH who had only second-degree BC affected
relatives were similar to those of patients without a FH
(26.3 vs. 26.4 mm, p = 0.960). Within the group of
patients with positive FH, the age at which the affected
relative was diagnosed with BC did not correlate with
tumor size (\50 years: 18.4 mm vs. C50 years: 21.0 mm,
p = 0.403).
We found similar results for the subgroup of patients
who found their tumors by BSE. Compared to patients
without FH, patients with positive FH found smaller
lesions (26.1 vs. 30.6 mm, p = 0.041). Patients with first-
degree BC affected relatives found their tumors at smaller
sizes than patients who had only second-degree BC
affected relatives (22.5 vs. 31.0 mm; MD -8.5, 95 % CI
-17.6 to -0.6, p = 0.044) and patients without FH (22.5 vs.
30.6 mm; MD -8.1, 95 % CI -14.4 to -1.7, p = 0.013).
Patients with positive FH and only second-degree BC
affected relatives identified their tumors at a similar size as
those with negative FH (31.0 vs. 30.6 mm, p = 0.902).
Within the group of patients with positive FH, the age at
which the affected relative was diagnosed with BC was not
significantly correlated with tumor size (\50 years:
23.9 mm vs. C50 years: 22.9 mm, p = 0.841).
Table 1 Breast cancer patients
(B70 years) with positive FH of
BC (n = 244): Degree of
relationship, number of affected
relatives, and age of the affected
relative at the time that her BC
was diagnosed
BC breast cancer, FH family
history
1 In one case, FH showed that
the father of the patient had
been diagnosed with BC at the
age of 80 years; in a second
case, one/a brother of the patient
was diagnosed at the age of
38 years. According to the age
segments, these cases were
considered as ‘‘\50 years’’
(brother) and ‘‘C50 years’’
(father)
Characteristic n (%)
First-degree relatives 159 (65.2)
Second-degree relatives 85 (34.8)
First-degree relatives 159
Relative diagnosed before age 501 70 (44.0)
Relative diagnosed C50 years1 88 (55.4)
Relative’s age unknown 1 (0.6)
One family member affected with BC 141 (88.7)
Two family members affected with BC 17 (10.7)
Three family members affected with BC 1 (0.6)
Mean number 1.1
Second-degree relatives 85
Relative diagnosed before age 50 10 (11.8)
Relative diagnosed C 50 years 38 (44.7)
Relative’s age unknown 37 (43.5)
One family member affected with BC 68 (80.0)
Two family members affected with BC 13 (15.3)
Three family members affected with BC 3 (3.5)
Four family members affected with BC 1 (1.2)
Mean number 1.3
Entire group of patients with positive FH (first degree and second-degree relatives) 244
One family member affected with BC 188 (77.1)
Two family members affected with BC 43 (17.6)
Three family members affected with BC 11 (4.5)
Four family members affected with BC 2 (0.8)
Mean number 1.3
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Discussion
The Collaborative Group on Hormonal Factors in Breast
Cancer reported that 12.9 % of women with BC had first-
degree relatives with a history of BC [1]. This review
analyzed 52 epidemiological studies in which 58,209 BC
patients were analyzed. The results of this large data col-
lection are approximately comparable with our data
(15.3 % of the BC patients had first-degree relatives
affected by BC).
Table 2 Comparison between a
cohort of 1,037 BC patients
(B70 years) with and without
FH of BC
AJCC American Joint
Committee on Cancer, UICC
International Union Against
Cancer [10, 11]
Statistically significant data (the
level of significance p \ 0.05)
are highlighted in bold
Variable Family history (positive)
n = 244
Family history (negative)
n = 793 (%)
p value
Age (years)
Mean 53.8 54.8 0.201
Median 54 56
Tumor detection method
Breast self-examination 132 (54.1) 468 (59.0)
Radiologic examination 78 (32.0) 175 (22.1) 0.008
Clinical breast examination (by
physician)
24 (9.8) 127 (16.0)
Other method 4 (1.6) 9 (1.1)
Unknown 6 (2.5) 14 (1.8)
Tumor size (mm)
Mean 21.8 26.4 0.003
Median (range) 17 (0.5–220) 20 (0–210)
Tumor category
T0 0 2 (0.2) <0.001
T1 159 (65.1) 405 (51.1)
T2 68 (27.9) 296 (37.3)
T3 10 (4.1) 61 (7.7) T3/T4:
0.054
Non-inflammatory T4 7 (2.9) 29 (3.7)
Bilateral synchronous carcinoma 5 (2.1) 15 (1.9) 0.80
AJCC/UICC TNM stage
I 119 (48.8) 284 (35.8) <0.001
II 82 (33.6) 324 (40.9)
III 37 (15.2) 142 (17.9)
IV 6 (2.4) 43 (5.4) 0.059
Histologic subtype
Ductal invasive 171 (70.7) 609 (77.3)
Lobular invasive 41 (16.9) 92 (11.7) 0.037
Rare types 30 (12.4) 87 (11.0)
Not available 2 5
Grading
G1/2 154 (66.1) 400 (53.4)
G3 79 (33.9) 349 (46.6) <0.001
Not available 11 44
Hormonal receptor status
Positive 205 (86.5) 614 (80.8) 0.052
Negative 32 (13.5) 146 (19.2)
Not available 7 33
HER2 status, 2002–2009 n = 124 (%) n = 339 (%)
Positive 19 (15.4) 61 (18.1) 0.57
Not available 1 2
Triple-negative subtype 8 (6.5) 46 (13.6) 0.007
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Our study confirms previously published data [8], which
demonstrated that in a cohort of BC patients, the tumors of
women who had a positive FH for BC were more often
found by RBE compared to women who had no BC
affected relatives. This might result from the fact that
women with a family BC history, obviously influenced by
personal and familial experiences with BC, generally use
BC screening more often than women without such history
[2–6]. It is not possible to determine precisely to what
extent the higher motivation for mammography can be
attributed to the women’s own initiative, the direct influ-
ence of family members (e.g. mother–daughter communi-
cation) or the motivating influence of their doctors who are
aware of the positive FH and incorporate this information
into their mammography referral practices. However, this
positive effect of increased use of and adherence to BC
screening is essentially due to a particular subgroup of
patients with positive FH, namely those whose first-degree
relatives were affected and those whose relatives were
diagnosed with BC at an earlier age (\50 years). When
more distantly related relatives (second-degree relatives) or
older relatives (C50 years of age) were diagnosed with BC,
the motivation to have BC screening could not be posi-
tively influenced. The tumors of these patients were simi-
larly often detected by RBE as those of women without FH.
We observed a similar pattern in the analysis of tumor
size. The tumors of patients with positive FH for BC were
significantly smaller compared to tumors of patients with
negative FH and, again, this positive effect was primarily
determined by the patients with first-degree BC affected
relatives. In contrast, patients who had only second-degree
BC affected relatives had similar tumor sizes to patients
without a FH for BC. These findings are consistent with
those of Tracy et al. [6], who also showed that the degree of
Table 3 Patient’s age according to FH of BC
MD (95 % CI) p value
Degree of relationship
0. no FH: 54.8 years
1. First-degree FH: 55.2 years
2. Second-degree FH: 51.2 years
Overall 0.007
1 versus 0 0.4 (-1.4, 2.2) 0.652
2 versus 0 -3.6 (-5.9, -1.3) 0.002
2 versus 1 -4.0 (-6.7, -1.2) 0.004
Number of affected relatives
Overall 0.322
1 affected relative: 53.5 years
C1 affected relative: 54.8 years
1 versus C1 1.2 (-1.9, 4.3) 0.440
Age of the affected relative at the time that her BC was diagnosed
0. no FH: 54.8 years
1. FH, \50 years: 51.7 years
2. FH, C50 years: 56.1 years
Overall 0.008
1 versus 0 -3.1 (-5.4, -0.8) 0.009
2 versus 0 1.3 (-0.6, 3.3) 0.175
1 versus 2 -4.4 (-7.3, -1.6) 0.002
MD mean difference, CI confidence interval, FH family history, BC breast
cancer
Statistically significant data (the level of significance p \ 0.05) are high-
lighted in bold
Table 4 Tumor detection method (radiological breast examination
vs. self-examination) according to FH of BC
OR (95 % CI) p value
Degree of relationship
0. no FH
RBE: n = 175 (27.2 %); SE: n = 468
(72.8 %)
1. First-degree FH
RBE: n = 60 (43.8 %); SE: n = 77
(56.2 %)
2. Second-degree FH
RBE: n = 18 (24.7 %); SE: n = 55
(75.3 %)
Comparison for RBE: Overall <0.001
1 versus 0 2.00 (1.43, 3.05) <0.001
2 versus 0 0.88 (0.50, 1.53) 0.641
1 versus 2 2.38 (1.27–4.54) 0.007
Number of affected relatives
Overall 0.008
1 affected relative
RBE: n = 56 (34.6 %); SE: n = 106
(65.4 %)
C1 affected relative
RBE: n = 22 (45.8 %); SE: n = 26
(54.2 %)
Comparison for RBE
C1 versus 1 1.60 (0.83, 3.10) 0.158
Age of the affected relative at the time that her BC was diagnosed
0. no FH
RBE: n = 175 (27.2 %); SE: n = 468
(78.2 %)
1. FH, \50 years
RBE: n = 35 (47.3 %); SE: n = 39
(52.7 %)
2. FH, C50 years
RBE: n = 35 (33.7 %); SE: n = 69
(66.3 %)
Overall 0.008
1 versus 0 2.40 (1.47, 3.90) <0.001
2 versus 0 1.36 (0.87, 2.10) 0.177
1 versus 2 1.79 (1.00, 3.23) 0.067
OR odds ratio, CI confidence interval, FH family history, BC breast cancer,
RBE radiological breast examination, SE self examination
Statistically significant data (the level of significance p \ 0.05) are high-
lighted in bold
104 F. D. Schwab et al.
123
relationship between relatives with BC affected the likeli-
hood of using BC screening. Furthermore, the authors
found that BC death in a family is a stronger predictor for
the use of BC screening.
Our results confirm the findings of recent studies, which
showed that women with affected first-degree relatives
were more likely to have smaller carcinomas and more
often early disease stage [7–9]. Furthermore, our study
confirms data from other studies which showed no signif-
icant differences with regard to tumor size and stage
between patients who had only second-degree relatives
affected with BC and patients without FH for BC [7, 8].
The phenomenon that patients with a first-degree BC
affected relative had smaller tumors at diagnosis might be
explained by more diligent use of BC screening amongst
women who considered themselves to be at increased risk
of developing the disease. However, we also observed this
phenomenon in patients who detected their tumors by self-
examination. In these cases, the personal experience of
having a close family member with BC was so influential
that they became more aware of the necessity of self-
examination and perceived changes earlier, thus leading to
the identification of smaller tumors. Sinicrope et al. [12],
who examined communication about BC prevention
between BC affected mothers and their daughters, found
that BC prevention behaviors were associated with corre-
sponding advice such as to have a mammogram (51 %) and
perform BSE (39 %). Interestingly, the increased aware-
ness of BC risk does not result in a behavioral change to a
more preventive lifestyle, such as weight control or
reduction of alcohol consumption [13].
The data regarding the relationship between FH of BC
and tumor characteristics are inconsistent. Some recent
studies found that women with a positive FH had tumors
with a generally more favorable prognostic profile [8, 9],
while others suggested that the characteristics of BC in
patients with a positive FH do not differ substantially
between those with and without relatives affected by BC
(overview in [3, 8]); further studies showed that FH was
associated with an increased risk of triple negative and HR-
negative/HER2-expressing BC [14]. In our study, women
with a positive FH had tumors with more favorable prog-
nostic profiles as assessed by tumor size, disease stage,
histologic grading, HR status and triple negative subtype.
Malone et al. [8] reported in a recently published study,
which examined a population-based cohort of younger BC
patients, that those with a first-degree FH, compared with
their counterparts without such a FH, had a better prognosis
(40 % reduction in the risk of dying). The fact that patients
with a positive FH have BC screening more often and
might have more favorable tumor characteristics, support
data which demonstrated a better prognosis for BC patients
with a positive FH.
Table 5 Tumor size according to FH of BC. I. All patients; II.
Tumors found by self-examination
MD (95 % CI) p value
All patients
Degree of relationship
0. no FH: 26.4 mm
1. First-degree FH: 19.3 mm
2. Second-degree FH: 26.3 mm
Overall 0.001
1 versus 0 -7.1 (-11.0, -3.2) <0.001
2 versus 0 -0.1 (-5.3, 5.0) 0.960
1 versus 2 -6.9 (-13.0, -0.9) 0.025
Number of affected relatives
Overall 0.019
1 affected relative: 21.3 mm
C1 affected relative: 23.4 mm
C1 versus 1 2.2 (-4.7, 9.1) 0.535
Age of the affected relative at the time that her BC was diagnosed
0. no FH: 26.4 mm
1. FH, \50 years: 18.4 mm
2. FH, C50 years: 21.0 mm
Overall 0.001
1 versus 0 -8.0 (-13.1, -3.0) 0.002
2 versus 0 -5.4 (-9.6, -1.1) 0.013
1 versus 2 -2.7 (-3.6, 8.9) 0.403
II. Tumors found by self-examination
Degree of relationship
0. no FH: 30.6 mm
1. First-degree FH: 22.5 mm
2. Second-degree FH: 31.0 mm
Overall 0.041
1 versus 0 -8.1 (-14.4, -1.7) 0.013
2 versus 0 0.5 (-6.9, 7.8) 0.902
1 versus 2 -8.5 (-17.6, -0.6) 0.044
Number of affected relatives
Overall 0.082
1 affected relative: 24.5 mm
C1 affected relative: 32.5 mm
C1 versus 1 8.1 (-3.2, 19.3) 0.160
Age of the affected relative at the time that her BC was diagnosed
0. no FH: 30.6 mm
1. FH, \50 years: 23.9 mm
2. FH, C50 years: 22.9 mm
Overall 0.026
1 versus 0 -6.6 (-15.0, 1.6) 0.114
2 versus 0 -7.6 (-14.0, -1.3) 0.019
1 versus 2 1.0 (-8.9, 11.0) 0.841
MD mean difference, CI confidence interval, FH family history, BC
breast cancer
Statistically significant data (the level of significance p \ 0.05) are
highlighted in bold
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There are particular factors which must be considered in
the interpretation of our findings. In the canton of Basel
and the adjoining region of Northwestern Switzerland,
there is no publicly funded organized mammography
screening program. All interested and motivated women,
however, have free access to mammography. In such an
environment, the utilization of RBE for early BC detection
is strongly dependent on the women’s motivation and own
initiative (opportunistic screening) as well as the recom-
mendation by her physician. For the purpose of our study,
i.e. to test whether the knowledge and experience of a BC
in the family increases BC awareness, a patient-driven
screening setting is better suited than a general screening
setting. Furthermore, the referral practice for mammogra-
phy, particularly in younger women, might be influenced
by physicians who are aware of the positive FH of their
patients. However, this motivating impact is hard to assess
in individual cases.
In the future, the impact of FH on BC screening may
become less important due to the broader acceptance and
use of general screening programs. Furthermore, in Wes-
tern countries, the number of potential female relatives
who could potentially develop BC is reduced simply
through the development of generally smaller, nuclear
families.
Strengths and limitations
During the last decade, there have only been a few studies
which evaluated the impact of FH on BC detection and
tumor size in BC patient cohorts [7–9]. However, most of
them reported only data on tumor size and stage [7], or
tumor size and pathological/biological features [9] but did
not consider tumor detection method. Malone et al. [8]
applied a more comprehensive approach and reported both
tumor size/stage and detection method. However, the
authors, whose findings were in part similar to our study,
restricted their analysis to younger patients (B45 years) and
did not study a current cohort (they ascertained BC cases
diagnosed between 1983 and 1992). To our knowledge, our
study is the first comprehensive analysis of the impact of FH
on BC detection and tumor size based on a more recent
population-based cohort (1990–2009), which does not
exclusively consider a subgroup of younger BC patients. By
analyzing a cohort with a broader age segment, we could
demonstrate that the positive effect of first-degree rela-
tionship is not only present in younger women (BC patients
B45 years represent approximately only the youngest 15 %
of a Western BC cohort) but also in patients in whom BC is
usually diagnosed (the median age of the entire cohort of the
BC patients documented in our Swiss database was
61 years; patients B70 years of age comprise 73 % of the
entire cohort of BC patients). Our findings are strengthened
by the ability to consider not only degree of relationship but
also to assess the confounding effects of number of affected
relatives and the age of the affected relative at the time that
her BC was diagnosed. We deliberately did not consider
BRCA1/BRCA2 mutation carrier separately. Due to the
infrequent nature of BRCA1/BRCA2 mutations, even in
women with a first-degree history, these mutations do not
play an important role in the general behavior of women
regarding mammography screening [8].
The following limitations of our study must be consid-
ered. Firstly, our study comes from a single region of a
small country with a high socioeconomic status and all
inhabitants have universal access to health care. Secondly,
our study relies on information obtained by patients‘ self-
reporting of FH. It is possible that in some cases the
patients failed to accurately recall their FH or the complete
FH might not be known to all women. Yoon et al. [15]
reported that although 96 % of the respondents of a
national survey in the USA believed that their FH infor-
mation is important for their own health, \30 % had
actively collected such information from relatives. Fur-
thermore, the entire FH regarding malignant diseases may
not always be known, since such topics might either not be
discussed or purposely concealed from the rest of the
family.
Conclusions
Women with a first-degree relative affected by BC or a
relative who was diagnosed with BC at younger age have
been sufficiently touched by that experience to prompt
them to be more diligent in attending mammography
screening, and thus be diagnosed earlier, than someone
who has not had this experience. The increased awareness
of BC risk, probably a result of personal experience from a
close relative, decreases if the relationship is more distant.
In patients who have only second-degree relatives, the
tumors are diagnosed similarly often by RBE and are of a
similar size compared to BC patients without FH.
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